Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2026)

Immuneering's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $214.8 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 323.84% year-over-year to $214.8 million; the TTM figure through Mar 2026 stood at $727.9 million (up 192.29% YoY), while the FY2025 annual figure was $232.0 million, up 340.08% from the prior year.
• Liabilities and Shareholders Equity was $214.8 million for Q1 2026 at Immuneering, down from $232.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $241.1 million in Q3 2025 to a low of $40.1 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $121.4 million across 5 years, with a median of $113.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 48.61% in 2024, then jumped 340.08% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $122.4 million in 2022, then fell by 16.17% to $102.6 million in 2023, then slumped by 48.61% to $52.7 million in 2024, then surged by 340.08% to $232.0 million in 2025, then decreased by 7.4% to $214.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $214.8 million (Q1 2026), $232.0 million (Q4 2025), and $241.1 million (Q3 2025), per Business Quant data.